Can at-home dermarollers give the same results as in-office microneedling or is that just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.
|Articles|June 27, 2023
Pointers With Portela: Reviewing Micro-Needling, Retinol, and Sunscreen
Author(s)Dustin Portela, DO
In this week’s Pointers With Portela, the 208SkinDoc reviews questions from social media about micro-needling, retinol, and sunscreen use.
Advertisement
- How often should you do micro-needling?
- When can I start using retinol?
- What time of day should I stop applying sunscreen?
Questions can be submitted via Portela's
Opinions expressed are that of Portela and do not express the views or opinions of Dermatology Times®.
Advertisement
Related to this article
The FDA approval, based on 36-week data from the phase 3 BRAVE-AA-PEDS trial, extends baricitinib access to patients as young as 12 years old with severe alopecia areata.
Guselkumab met primary and major secondary endpoints in the phase 4 STAR study, improving axial PsA symptoms and MRI-confirmed inflammation.
Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of September.
Three experimental hair loss mechanisms are moving through late-stage trials for the first time in decades, and the data are worth knowing before patients ask.
Alexandra Charrow, MD, discussed biologic selection, deroofing, and emerging procedural approaches to hidradenitis suppurativa at Maui Derm NP+PA Fall 2026.
Week 28 data from the phase 2a EVERLAST-A trial showed PASI 100 responses increased to 71.4% despite no additional ORKA-001 dosing after week 4.
Immunovant will discontinue development of imeroprubart in cutaneous lupus erythematosus after the phase 2b study failed to meet its primary endpoint.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Baricitinib for Adolescents With Severe Alopecia Areata
2
Tremfya Meets Primary, Major Secondary Endpoints in Phase 4 STAR Study of Axial PsA
3
Dr. Charrow Highlights Earlier Biologic Use and Deroofing in Hidradenitis Suppurativa
4
The Aesthetic Edge: September 2026
5